Alerts will be sent to your verified email
Verify Email
TRIMURTHI
|
Novelix Pharma
|
Fervent Synergies
|
Aviva Inds
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-17.5 % | -7.16 % | -0.72 % |
|
5yr average Equity Multiplier
|
1.26 | 1.01 | 1.29 |
|
5yr Average Asset Turnover Ratio
|
0.84 | 0.33 | 0.08 |
|
5yr Avg Net Profit Margin
|
-14.11 % | -11.74 % | -54.19 % |
|
Price to Book
|
5.47 | 1.68 | 30.17 |
|
P/E
|
99.44 | 24.95 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
29.1 Days | 0.0 | 1390.57 Days |
|
Inventory Days
|
34.04 Days | 0.0 | 0.74 Days |
|
Days Receivable
|
55.38 Days | 0.0 | 2188.29 Days |
|
Days Payable
|
55.7 Days | 0.0 | 183.45 Days |
|
5yr Average Interest Coverage Ratio
|
-17.77 | 303.36 | 1.24 |
|
5yr Avg ROCE
|
-15.4 % | -6.97 % | -0.49 % |
|
5yr Avg Operating Profit Margin
|
-16.49 % | -8.29 % | -54.26 % |
|
5 yr average Debt to Equity
|
0.05 | 0.0 | 0.2 |
|
5yr CAGR Net Profit
|
35.78 % | 76.96 % | n/a |
|
5yr Average Return on Assets
|
-13.36 % | -7.13 % | -0.52 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
53.33 % | 74.75 % | 65.3 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-13.59 % | 1.42 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Novelix Pharma
|
Fervent Synergies
|
Aviva Inds
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|